13C Pyruvate DNP MR Spectroscopy for Lymphoma Treatment Response Assessment

• Status: Not yet recruiting
• Trial end date: 2024-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This study has two stages and the aims are as follows:

Aim 1:

In Stage 1 of this study, the investigators aim to recruit first-time diagnosed lymphoma patients, to understand the changes of metabolites before and after treatment, and to evaluate the ability of hyperpolarized 13C-labeled pyruvate from dynamic nuclear polarization (DNP) magnetic resonance spectroscopy (MRS) for detecting early treatment response in these patients.

The pre-treatment metabolic imaging biomarker levels will be compared to the followings:

1. Post-treatment metabolites from 13C-pyruvate DNP MRS after the first week of chemotherapy

2. Interval change in tumor size

3. ADC values from diffusion weighted imaging (DWI), SUV values from 18F-FDG PET/CT before and after the first week of chemotherapy

4. Pre-treatment and interim follow up SUV values from 18F-FDG PET/CT

5. Post-treatment outcome and to understand the change of metabolites before and after treatment and if possible, evaluate treatment outcome using the above imaging biomarkers

Aim 2:

In Stage 2 of this study, the investigators aim to recruit lymphoma patients with proven relapse after treatment, to understand the changes of metabolites before and after treatment, to compare the metabolite changes with Stage 1 patients and to evaluate the ability of hyperpolarized 13C-labeled pyruvate from DNP MRS for detecting early treatment response in these patients.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Chang Gung Memorial Hospital

Criteria

Inclusion Criteria:

1. Able to understand and provide signed informed consent

2. Willing to receive 13C-pyruvate DNP MRS and return for post-treatment evaluation for the scheduled follow up imaging about 1 week after initiation of chemotherapy.

3. Willing to receive therapy and follow-up as suggested by the tumor board and combined conference meeting in our institution

4. Presence of enlarged neck lymph nodes and/or spleen to serve as localized target for 3C-pyruvate DNP MRS

The exclusion criteria include:

1. Contraindicated to MRI study: such as cardiac pacemaker, cochlear implantation, metallic object within eyeball

2. Patients that refuse to, or has poor ability of understanding and comply study conditions, such as severe dementia or difficulty in mobilit

Exclusion Criteria:

1. Contraindicated to MRI study: such as cardiac pacemaker, cochlear implantation, metallic object within eyeball

2. Patients that refuse to, or has poor ability of understanding and comply study conditions, such as severe dementia or difficulty in mobilit